Tarun Chakravarty

Showing 1-11 of 11 articles

Interventions for heart failure

Allogeneic cardiosphere-derived cells for the treatment of heart failure with reduced ejection fraction: the Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells (DYNAMIC) trial

Chakravarty T, Henry T, Kittleson M, Lima J, Siegel R, Slipczuk L, Pogoda J, Smith R, Malliaras K, Marbán L, Ascheim D, Marbán E, Makkar R

July 17, 2020 | 10.4244/EIJ-D-19-00035

Interventions for valvular disease

High-pressure post-dilation following transcatheter valve-in-valve implantation in small surgical valves

Chakravarty T, Cox J, Abramowitz Y, Israr S, Uberoi A, Yoon S, Dey D, Zadeh P, Cheng W, Makkar R

June 20, 2018 | 10.4244/EIJ-D-17-00563

Characteristics and outcome following transcatheter aortic valve replacement in patients with severe aortic stenosis with low flow

Abramowitz Y, Chakravarty T, Pibarot P, Maeno Y, Kawamori H, Anderson D, Mangat G, Nakamura M, Cheng W, Makkar R

December 8, 2017 | 10.4244/EIJ-D-17-00139

Interventions for valvular disease

Optimal sizing for SAPIEN 3 transcatheter aortic valve replacement in patients with or without left ventricular outflow tract calcification

Maeno Y, Abramowitz Y, Jilaihawi H, Israr S, Yoon S, Sharma R, Kazuno Y, Kawamori H, Miyasaka M, Rami T, Mangat G, Takahashi N, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Makkar R

April 7, 2017 | 10.4244/EIJ-D-16-00806

Interventions for valvular disease

Leaflet motion abnormality after TAVI: genuine threat or much ado about nothing?

Chakravarty T, Abramowitz Y, Jilaihawi H, Makkar R

September 18, 2016 | 10.4244/EIJV12SYA7

Interventions for valvular disease

The clinical impact of vascular complications as defined by VARC-1 vs. VARC-2 in patients following transcatheter aortic valve implantation

Okuyama K, Jilaihawi H, Abramowitz Y, Kashif M, Patel J, Pokhrel H, Chakravarty T, Nakamura M, Cheng W, Makkar R

August 5, 2016 | 10.4244/EIJV12I5A104

Coronary interventions

Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment

Pyxaras S, Hunziker L, Chieffo A, Meliga E, Latib A, Park S, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar R, Palacios I, Kim Y, Buszman P, Chakravarty T, Sheiban I, Mehran R, Margey R, Agnihotri A, Marra S, Capodanno D, Leon M, Moses J, Fajadet J, Lefèvre T, Morice M, Erglis A, Tamburino C, Alfieri O, Serruys P, Colombo A, Naber C

August 5, 2016 | 10.4244/EIJV12I5A102

Interventions for valvular disease

Feasibility and safety of balloon-expandable transcatheter aortic valve implantation with moderate or without predilatation

Abramowitz Y, Jilaihawi H, Chakravarty T, Kashif M, Matar G, Hariri B, Patel J, Sharma R, Cheng W, Makkar R

February 19, 2016 | 10.4244/EIJV11I10A229

Clinical impact of coronary protection during transcatheter aortic valve implantation: first reported series of patients

Abramowitz Y, Chakravarty T, Jilaihawi H, Kashif M, Kazuno Y, Takahashi N, Maeno Y, Nakamura M, Cheng W, Makkar R

September 22, 2015 | 10.4244/EIJV11I5A112

Heart-rate adjustment of transcatheter haemodynamics improves the prognostic evaluation of paravalvular regurgitation after transcatheter aortic valve implantation

Jilaihawi H, Chakravarty T, Shiota T, Rafique A, Harada K, Shibayama K, Doctor N, Kashif M, Nakamura M, Mirocha J, Rami T, Okuyama K, Cheng W, Sadruddin O, Siegel R, Makkar R

August 20, 2015 | 10.4244/EIJY14M12_08

Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry

Meliga E, De Benedictis M, Chieffo A, Latib A, Park S, Kim Y, Onuma Y, Capranzano P, Jegere S, Makkar R, Palacios I, Buszman P, Bande M, Chakravarty T, Mehran R, Naber C, Scrocca I, Margey R, Leon M, Moses J, Fajadet J, Lefèvre T, Morice M, Erglis A, Tamburino C, Alfieri O, Conte M, Serruys P, Colombo A

November 29, 2013 | 10.4244/EIJV9I7A133

Latest news

NEW ISSUE

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

AHEAD OF PRINT

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

AHEAD OF PRINT

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

AHEAD OF PRINT

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.